术前激素治疗在局限性前列腺癌治疗中的地位:一项基于6个随机对照试验的荟萃分析

背景:研究已证实术前激素治疗减低了前列腺癌患者的临床分期和病理分期,减少了切缘阳性率,但是并没有提高患者的无病生存率.目前术前激素治疗前列腺癌的价值尚无定论.目的:评价术前激素治疗在治疗局限性前列腺癌中的作用.方法:计算机检索PubMed、EMBASE、Cochrane Library(2009年第4期)、中国生物医学文献数据库、中国期刊全文数据库、维普中文科技期刊数据库中2009年10月前发表的文章,手工检索相关领域的杂志.纳入随机对照试验,经病理学及细胞学检查确诊为局限性前列腺癌的患者,性别和民族不限,没有严重的心肺疾病;排除晚期或是复发的前列腺癌患者.同时从纳入文献的参考文献中查找符合要求的随机对照试验.采用国际Cochrane协作组提供的Revman 5.0软件进行统计分析.主要评价无病生存率、切缘阳性率、淋巴结阳性率、精囊浸润率4个结局指标.结果与结论:共纳入6篇随机对照试验合计1 027人,meta分析结果显示:与单纯的前列腺癌手术相比,术前激素治疗联合前列腺癌手术在无病生存率[RR=I.02,95%CI(0.89,1.17)],淋巴结阳性率[RR=0.86,95%CI(0.47,1.57)]、精囊浸润率[RR=1.09,95%CI(0.74,1.59)]方面差异无显著性意义,而在手术切缘阳性率[RR=0.46,95%CI(0.32,0.66)]方面差异有显著性意义.提示术前激素治疗联合前列腺癌根治术能减低局限性前列腺癌患者的手术切缘阳性率,但是并不能提高患者的无病生存率、淋巴结阳性率、精囊浸润率.

Role of preoperative hormone therapy in localised prostate cancer: Meta-analysis based on six randomized controlled trials

BACKGROUND: Previous research has demonstrated that preoperative hormone therapy relieved clinical and pathological stages of prostatic carcinoma patients, reduced positive ratio of incisal margin; however, it did not increase disease-free survival rate. Worth of preoperative hormone therapy for prostatic carcinoma remains unclear. OBJECTIVE: To assess the role of preoperative hormone therapy in localised prostate cancer. METHODS: Articles were searched from PubMed, Embase, Cochrane Library (No. 4, 2009), C...